---
layout: default
title: Dr. Ted Pincus (ClinDat) 聯繫信件
parent: 可整合應用程式評估
grand_parent: SMART on FHIR
nav_exclude: true
---

# Dr. Ted Pincus (ClinDat) 聯繫信件

**目標**：探討風濕科學術合作
**優先級**：中（Phase 3）
**聯繫方式**：tedpincus@gmail.com

---

## 信件內容

**Subject:** Academic Collaboration: AI-Powered Drug Repurposing for Rheumatic Diseases - TwTxGNN x ClinDat

---

Dear Dr. Pincus,

I am writing to explore a potential academic collaboration between TwTxGNN and ClinDat, your rheumatology monitoring platform.

### About TwTxGNN

TwTxGNN is an open-source drug repurposing platform that leverages Harvard's TxGNN knowledge graph model (published in *Nature Medicine*, 2023) to predict potential new indications for existing medications.

**Our Autoimmune Disease Coverage:**
- 17 drugs with autoimmune disease predictions
- 16 predicted indications including rheumatoid arthritis, lupus, and other rheumatic conditions
- L1-L5 evidence classification with ClinicalTrials.gov and PubMed validation

**Website:** https://twtxgnn.yao.care/
**GitHub:** https://github.com/yao-care/TwTxGNN

### Why This Collaboration

Your pioneering work on RAPID3 (Routine Assessment of Patient Index Data) and patient-reported outcomes in rheumatology provides a unique opportunity for drug repurposing validation:

1. **Outcome-Based Validation**: ClinDat's disease activity tracking (DAS28, RAPID3) can help validate whether AI-predicted drug candidates actually improve patient outcomes.

2. **Treatment-Resistant Patients**: When disease activity scores indicate inadequate treatment response, TwTxGNN predictions can suggest alternative therapeutic options.

3. **Real-World Evidence**: Combining AI predictions with ClinDat's longitudinal patient data could generate valuable real-world evidence.

### Proposed Collaboration

1. **Data Integration**
   - Display TwTxGNN drug repurposing candidates within ClinDat workflow
   - Trigger suggestions when RAPID3/DAS28 scores indicate poor response

2. **Validation Study**
   - Track outcomes of patients who receive repurposed drugs
   - Generate evidence for AI prediction validation

3. **Publication Opportunity**
   - Joint publication on AI-assisted rheumatology decision support
   - Contribute to the evidence base for precision rheumatology

### Technical Compatibility

| Item | TwTxGNN | ClinDat |
|------|---------|---------|
| FHIR Version | R4 | DSTU2 (upgradeable) |
| Data Format | JSON/FHIR | Proprietary |
| Integration | API available | SMART App |

### Next Steps

Would you be interested in:

1. A brief call to discuss the collaboration concept?
2. Reviewing our autoimmune disease drug predictions?
3. Exploring a pilot integration study?

I greatly admire your contributions to quantitative rheumatology and believe this collaboration could benefit patients with treatment-resistant rheumatic diseases.

Best regards,

**TwTxGNN Team**
https://twtxgnn.yao.care/

---

## 附件清單

- [ ] 英文版專案簡介：[project-intro-en.md](../project-intro-en)
- [ ] 自體免疫疾病藥物預測清單

---

## 背景資料

### Dr. Ted Pincus

- 風濕科醫師，RAPID3 評分系統開發者
- 長期倡導病患自我評估在風濕病學的應用
- ClinDat 平台創建者

### RAPID3 評分

- Routine Assessment of Patient Index Data 3
- 包含：功能性、疼痛、整體評估
- 計分範圍：0-30
- 可在 10 秒內完成評估

---

## 待辦事項

- [ ] 發送聯繫信件
- [ ] 整理 TwTxGNN 風濕疾病相關預測資料
- [ ] 準備學術合作提案
- [ ] 安排視訊會議
- [ ] 準備 IRB 相關文件（若需要）

---

*建立日期：2026-03-01*
